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ABSTRACT
Interstitial lung disease (ILO) can be separated into two
groups: (i) that in which the causes are known; and (ii)
that in which the etiologies have not been determined.
Meanwhile, complement is essential for the inflamma-
tory response and complement systems have been
recognized as factors involved in organizing ILO. In the
present study we investigated whether there were any
differences in complement-related membrane proteins
on lymphocytes and alveolar macrophages in bron-
choalveolar lavage fluids (BALF) between different ILO.
Bronchoalveolar lavage fluid samples were obtained
from 12 patients and eight healthy individuals.
Bronchoalveolar lavage fluid cells were incubated with
monoclonal antibodies (mAbs) against C3b/C4b
receptor (CR1), C3bi receptor (CR3), membrane
cofactor protein (MCP) and decay accelerating factor
(OAF) and were then labeled with fluorescein isothio-
cyanate-conjugated anti-mouse IgG. Cells were
analyzed using a flow cytometer.The results demon-
strate for the first time that CR3 and OAF are elevated
on alveolar macrophages, and that MCP and OAF are
increased on BALF lymphocytes in sarcoidosis. The
possible roles of complement-related membrane pro-
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teins in the pathogenesis of immune processes that are
ongoing in sarcoidosis are still obscure, but our results
may provide some useful information on the mecha-
nisms underlying sarcoidosis.
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INTRODUCTION
Interstitial lung disease can be separated into two groups,
one group for which the causes are known and the other
for which the etiologies have not been determined.
Although fibrosing mechanisms in the lungs have been
investigated in a variety of immune responses.!'? the
pathogenetic factors leading to an extreme course of
fibrosis remain obscure. Meanwhile, the complement
system, which is involved in all immune processes, has not
been extensively studied in interstitial lung disease so far.
Recently, the complement system has been recognized as
a factor involved in the fibrosing of lunqs.:' Some groups
have reported that the etiology of sarcoidosis is related to
the expression of complement receptors.v" Others have
shown the presence of increased numbers of activated
T cells that were considered as one of the hallmarks of the
alveolitis associated with sarcoidosis." In the present study
we investigated the expression of complement-related
membrane proteins on alveolar macrophages (AM) and
lymphocytes in bronchoalveolar lavage fluid (BALF) and
compared this among patients with various interstitial
lung diseases (ILD).
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METHODS
Patient profile
Twelve ILD patients were diagnosed on the basis of char-
acteristic clinical features and tests as shown in Table 1.
Bronchoalveolar lavage fluid samples were obtained from
these 12 patients and from eight healthy individuals. Local
ethical committee approval and fully informed written
consent from each individual was obtained. As shown in
Table 1, six patients were diagnosed as interstitial pneu-
monia (IP), mainly idiopathic interstitial pneumonia. Three
patients were diagnosed as sarcoidosis (Sa) and the
remaining three patients were diagnosed as eosinophilic
pneumonia (EP). As controls (MiSe), we used samples
obtained from healthy individuals and from the healthy
side of the lungs of patients suffering from lung cancer. For
Table 1. Clinical and physiological data of the study population
No. patients Age LDH CRP Pao2 %VC
(M/F) (years) (Il/L) (mg/dL) (mmHg)
MISC 8 (7/1) 63.7 ± 9.2 365.0 ± 88.4 0.6 ± 0.9 83.3 ± 10.8 102.6±17.3
IP 6 (3/3) 52.7 ± 26.1 401.3 ± 68.8 0.3 ± 0.3 70.9 ± 19.2* 88.2 ± 6.2
Sa 3 (3/0) 53.7 ± 15.0 303.0 ± 71.6 4.9 ± 4.0 83.6 ± 3.5 75.8 ± 8.3
EP 3 (1/2) 32.0 ± 11.3* 450.3 ± 137.3 0.2 ± 0.3 84.4 ± 7.1 106.4 ± 3.7
Data are the mean ± SD. P<0.05.
Ip, interstitial pneumonia; Sa, sarcoidosis, Ep, eosinophilic pneumonia; MISC, miscellaneous (control); LDH, lactate dehydrogenase; CRp,
C-reactive proteins; Vc, vital capacity.
Table2. Clinical details of patients with interstitial lung disease
No. Sex Age Dyspnea Pao2 %VC LDH ESR CXP Ga Points ACT SM
(years) (mmHg) (Il/L) (mm) scinti
IPl M 70 HJI 74.0 78.3 389 118 ++ ++ 8/14 2 1
IP2 F 19 HJ I 96.5 88.8 327 11 ++ ++ 4/14 1 0
IP3 F 20 HJ III 52.8 87.9 528 9 +++ ++ 11/14 3 0
IP4 M 68 HJ I 69.0 110.0 403 46 + + 3/14 1 1
IPS M 71 HJ III 50.3 ND 404 22 ++ ++ 10/12 3 1
IP6 F 69 HJ I 89.5 105.8 357 100 + 1/14 1 0
Sal M 45 HJ II 79.6 69.9 353 124 ++ ++ 11/14 3 1
Sa2 M 45 HJ I 86.4 ND 221 102 + ++ 5/12 2 0
Sa3 M 71 HJ I 84.7 81.7 335 54 ++ ++ 4/12 1 1
EPl M 25 HJ II 79.5 102.2 559 7 ++ ND 8/12 2 0
EP2 F 26 HJ III 92.6 106.6 296 5 ++ ND 5/10 2 0
EP3 F 45 HJ I 81.2 107.7 496 24 ++ ND 6/12 2 0
Ip, interstitial pneumonia; Sa, sarcoidosis; Ep, eosinophilic pneumonia; ACT, activity index; HJ, Hugh-Jones; NO, not done; CXp, degree of pul-
monary infiltration (chest X-ray); Ga scinti, according to previously criteria for a positive gallium-67 scan; SM 1, current smoker; SMO, non-smoker
or ex-smoker. For details, see Methods.
Eo
(%)
-----
3.1 ± 4.3
1.2 ± 2.8
2.2 ± 3.8
5.2 ± 3.9*
Bronchoalveolar lavage fluid data of control patients and patients with interstitial lung disease
------
Total cells AM Ly Neu
(x 104) (%) (%) (%)
16.5 ± 9.2 83.8 ± 13.5 10.7 ± 8.2 2.3 ± 1.7
27.2 ± 7.5* 84.4 ± 7.6 10.8 ± 7.3 3.7 ± 4.4*
20.9 ± 6.2* 89.2 ± 6.7 6.1 ± 3.6 2.2 ± 1.2
24.2 ± 9.3* 83.4 ± 7.7 9.1 ± 4.5 2.3 ± 0.6
---
Table 3.
MISC
IP
Sa
EP
Data are the mean ± SO. *P<O.OS.
MISC, miscellaneous (controls); Ip, interstitial pneumonia; Sa, sarcoidosis; Ep, eosinophilic pneumonia; AM, alveolar macrophages; Ly, lympho-
cytes; Neu, neutrophils; Eo, eosinophils.
all controls, the lung that was lavaged was roentgeno-
graphically normal.
Next, we investigated the characteristics of patients when
they underwent bronchoalveolar lavage (BAL;Table 2) and
established a disease activity index (ACT) based on
changes induced after excerbation.
As for derivation of the ACT, we checked the severity of
dyspnea (Hugh-Jones dyspnea category), Pa02, % vital
capacity (VC), lactate dehydrogenase (LDH), erythrocyte
sedimentation rate (ESR), chest X-ray and Ga scintigram.
We defined a scale of disease activity from 1 to 3 as
follows: two points were given to each item and the total
points were summed. When the ratio of acquired points to
the total was over 70%, the activity was 3 (ACT 3). In cases
where the ratio was below 30%, the activity was 1 (ACT 1).
Other scores (from 30 to 70%) were classified as ACT 2.
Cells
Lungs were lavaged by bronchofiberscopy with three
50 mL aliquots of sterile saline (3JOC). The lavage cells
were then separated by centrifugation at 200 9 for 10 min
at 4°C. The supernatant (5 mL) was frozen at -80°C for
subsequent analysis of complement breakdown products,
while the remainder of the lavage fluid was used for deter-
mination of the expression of complement-regulatory
membrane proteins. Complement breakdown products
were measured by commercially available ELISA test kits
(Fuji revio, Tokyo, Japan).
A total nucleated cell count in the BALF was obtained
using a Neubauer hemocytometer. Cytospin preparations
were stained with May-Grunwald-Giemsa stain and differ-
ential cell counts were performed on 200 cells. Results are
expressed as the total number of cells per mL lavage fluid.
Chemicals
Mouse anti-C3b/C4b receptor (CR1) and anti-C3bi
receptor (CR3) monoclonal antibodies (mAb) were pur-
chased from Becton Dickinson Laboratories (Mountain
View, CA, USA). Mouse anti-membrane cofactor protein
(MCP) and anti-decay accelerating factor (OAF) mono-
clonal antibodies (mAb) were purchased from Serotec
Laboratories (Mountain View, CA, USA).
Fluorescein isothiocyanate (FITC)-conjugated goat
antimouse IgG was obtained from Nakarai Co. (Kyoto,
City, Japan).
Cytofluorometry
Bronchoalveolar lavage fluid cells (1.5 X 104 cells/mL in
phosphate-buffered saline (PBS)) were incubated on ice
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with mAbs against CR1, CR3, MCP and OAF, then
labeled with FITC-conjugated anti-mouse IgG. Cells
were analyzed using a flow cytometer (FACScan, Becton
Dickinson).
Complement breakdown products (C4d, Bb, iC3b,
SC5b-9) were measured by ELISA methods.
Statistical analysis
The significance of differences between groups was
determined by the Student's unpaired t-test.
RESULTS
Clinical data of the study population
The EP group is composed of younger patients than the
MISC group. In the IP group, the Pa02 is significantly
lower than in the MISC group (P = 0.04).
Bronchoalveolar lavage cellular constituents in
the study population
Cellular contents are expressed as percentage values
(Table 3). In all controls (MISC), the BAL cytology showed
a normal differential cell count. The total number of cells
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Fig. 1 Complement breakdown products in bronchial alveo-
lar lavage fluid (BALF). (a) C4d, (b) Bb, (c) iC3b and (d) SCSb-9
in BALF were measured by ELISA methods. Data are the
mean ± SO. (0), miscellaneous; (_), interstitial pneumonia;
(0), sarcoidosis; (~), eosinophilic pneumonia. C4d is
increased significantly (P=O.03) in the sarcoidosis group; IC3b
is increased in the interstitial pneumonia group (P=O.OS).
112 R NAKAHARA ET AL.
in recovered fluid was greater in patients with IP (mean,
27.2 X 104) than in controls (16.5 X 104; P = 0.0108).
Similarly, in both Sa and EP groups the total number of
cells was greater than in the MISC group. For the con-
stituent cells, there were more neutrophils in the IP group
than in the MISC group and there were more eosinophils
in the EP group than in the MISC group.
Complement breakdown products in BALF
We compared the IP and the Sa groups (Fig. 1). In
the IP group, there was a tendency towards an increase
in iC3b (P = 0.05). In the Sa group, C4d was
increased significantly (P = 0.03), suggesting activa-
tion of complement.
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Fig. 2 Expression of complement control proteins on
lymphocytes in bronchial alveolar lavage fluids. (a) The
C3b/C4b receptor, (b) the C3bi receptor, (c) membrane
cofactor protein and (d) decay accelerating factor. The level of
each complement control protein is expressed as the mean
fluorescence channel. The results are given as the mean ± SO
of patient data. All current smokers are indicated with asterisks.
In the interstitial pneumonia (IP) group, inactive patients
(disease activity index ACT) = 1) are indicated by open circles
and active patients (ACT :2: 2) are indicated by closed cirlces.
The data are plotted as individual points for each subject.
For details, see Methods. Sa, sarcoidosis; Ep, eosinophilic
pneumonia; MISC, miscellaneous.
Fig. 3 Expression of complement control proteins on alveolar
macrophages in bronchial alveolar lavage fluids. (a) The
C3b/C4b receptor, (b) the C3bi receptor, (c) membrane cofac-
tor protein and (d) decay accelarating factor. The level of each
complement control protein is expressed as the mean fluores-
cence channel. The results are given as the mean ± SO of
patient data. All current smokers are ind icated with asterisks. In
interstitial pneumonia (IP) group, inactive patients (disease
activity index (ACT)= 1) are indicated by open circles and active
patients (ACT :2: 2) are indicated by closed circles. The data are
plotted as individual points for each subject. For details, see
Methods. Sa, sarcoidosis; Ep, eosinophilic pneumonia; MISC,
miscellaneous.
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Expression of complement control proteins on
lymphocytes in BALF
Expression of complement control proteins on
AM in BALF
The level of each complement control protein is expressed
as the mean fluorescence channel (MFI; Fig. 2).
There was no significant difference between the groups
with respect to complement receptors, while the comple-
ment-regulatory membrane proteins differed between the IP
and Sa groups. In the Sa group, the expression of MCP was
significantly increased (P = 0.02). Moreover, there was a
tendency towards increased expression of OAF (P = 0.09).
As for complement receptors, there was a tendency
towards an increased expression of CR3 in the Sa group
(P = 0.07) compared with CR3 in the IP group (Fig. 3).
With regard to complement-regulatory membrane pro-
teins, there was also a tendency towards an increased
expression of OAF (P = 0.09).
Correlation of complement breakdown
products (C4d, Bb, iC3b, SCSb-9) in BALF
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We investigated the correlation coefficients among the
complement breakdown products using the Spearman
rank correlation. There were significant correlations
between iC3b and C4d (r = 0.6997, P = 0.0003), iC3b
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Fig. 4 Correlation between the complement breakdown prod-
ucts (C4d, Bb, iC3b and SC5b-9) in bronchial alveolar lavage
fluids. There were significant correlations between (a) iC3b and
C4d (r=O.699, P=O.0003), (b) iC3b and Bb (r=O.607,
P=O.003) and (c) C4d and Bb (r=O.577, P=O.005).
Fig. 5 Correlations of complement-related membrane proteins
on lymphocytes. There was a correlation between (a) the
C3b/C4b receptor (CR1) and the C3bi receptor (CR3; r=0.779,
P<O.OOOl) and between (b) membrane cofactor protein (MCP)
and decay accelerating factor (OAF; r=0.448, P=O.036).
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and CR3 (r = 0.779, P < 0.0001; Fig. 5a,b). Moreover,
there was also a correlation between MCP and DAF
(r = 0.448, P = 0.036).
Correlations of complement-related
membrane proteins on AM
On AM, no correlation was found between the expression
of complement receptors; however, as for the amount of
complement regulatory proteins, there was a significant
correlation between MCP and DAF (r = 0.564, P = 0.005;
Fig. 6).
Correlations between the ACT and expressed
complement-related membrane proteins
We evaluated disease activity in the study population and
show the ACT in Table 2. Correlation coefficients were
investigated using the Spearman rank correlation. There
was no correlation between the ACT and complement
regulatory proteins on AM and on lymphocytes (Fig. 7).
There were also no significant correlations between the
ACT and complement receptors. However, there was a
tendency for CR1 on AM to be elevated in proportion to
the increase in ACT (Fig. 7).
The present study demonstrates that complement-related
membrane proteins on AM and lymphocytes in BALF are
increased in patients suffering from sarcoidosis.
The cells of the immune system secrete a variety of
mediators in response to invading substances. The com-
plement system is one of the protective systems possessed
by organisms. Some investigators have reported several
levels of complement control proteins in circulating blood
cells. 7,8 However, the complement control proteins in
BALF cells have not yet been fully examined and there are
no reports regarding the complement regulatory proteins
in these cells. Therefore, we investigated the expression of
complement control proteins, such as CR1, CR3, MCP
and DAF, on AM and BALF lymphocytes in ILD patients
and in healthy controls.
In the present study, MCP and DAF were found to be
expressed more dominantly on lymphocytes of BALF in
sarcoidosis and the levels of CR3 and DAF on AM were
elevated.
Membrane cofactor protein (CD46) controls the acti-
vation of autologous complement by operating as a
cofactor of factor I in the cleavage of C3b and C4b9 .
DISCUSSION
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Fig. 6 Correlations of complement-related membrane pro-
teins on alveolar macrophages. There was a significant
correlation between membrane cofactor protein (MCP) and
decay accelerating factor (DAF; r=O.564, P=O.005).
Fig. 7 Correlation between the disease activity index and the
expression of the C3b/C4b receptor (CR1) on alveolar
macrophages. (0), interstitial pneumonia; (0), sarcoidosis;
(6), eosinophilic pneumonia. *P<O.l O.
We investigated correlation coefficients among the comple-
ment-related membrane proteins using the Spearman rank
correlation. A strong correlation was evident between CR1
and Bb (r = 0.6073, P = 0.0027) and C4d and Bb
(r = 0.5771, P = 0.0049; Fig. 4a-c).
Correlations of complement-related
membrane proteins on lymphocytes
Oelay accelerating factor (COSS) is also one of the
complement regulatory proteins that inhibits the C3/CS
converting enzymes that activate C3 and CS. Oelay
accelerating factor is widely distributed in human cells
and tissues that contact the complement svstern.!"
In our consideration of the mechanism responsible for
the increase of MCP and OAF levels on BALF lymphocytes
in sarcoidosis, we included the possibility that complement
activation in the pulmonary compartment resulted in the
upregulation of MCP and OAF. We demonstrated signifi-
cantly elevated levels of complement breakdown products
(C4d, Bb, iC3b, SCSb-9) in BALF compared with levels
found in peripheral blood. Moreover, there were correla-
tions between the levels of iC3b and C4d, iC3b and
Bb and C4d and Bb. The strong correlations led us to
conclude that complement activation occurred in the
pulmonary compartment. Results from a previous studv!'
raise the possibility that complement regulatory proteins
on cell membranes are upregulated after complement
activation. Therefore, in sarcoidosis, the upregulation of
MCP and OAF on lymphocytes may also be the result of
complement activation in the alveolar spaces.
Furthermore, we suggest the possibility of the influence
on BALF cells of cytokines released into the alveolar
spaces. We have reported that macrophage-colony stimu-
lating factor (M-CSF), one of the cytokines, increased the
levels of CR1, CR3, MCP and OAF on monocytes in
human peripheral blood.'? Other researchers have
demonstrated that OAF is upregulated by interleukin (IL)-4
and IL-l B. 13,14 In the pulmonary compartment, such
cytokines may affect the complement control proteins on
BALF lymphocytes. In sarcoidosis, the elevated C04/8
ratio of BALF lymphocytes is characteristic of BALF Iym-
phocytes.P'" This increase is interpreted as secondary to
the increased number of C04 + lymphocytes (helper
T cells) and to the activated stage of the lymphocytes due
to continuous stimulation by various ontiqens." The MCP
and OAF on lymphocytes may be influenced by such
continuous stimulation as MCP and OAF are considered
to be the major factors involved in host cell protection
from homologous C3 activation on the cell rnernbrcnes.'?
The results for complement control proteins on AM
indicated the tendency to increased levels of CR3 and
OAF in sarcoidosis. CR3 has important functions both as
an adhesion molecule and as a membrane receptor
mediating recognition of diverse ligands. 20 This comple-
ment receptor operates to transmit some stimulatory
signals in inflammatory sites.
Pettersen et 0/. 21 also found increased complement
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receptors on AM from patients with sarcoidosis. CR3 is
expressed on phagocytic cells and plays a major role in
the clearance and phagocytosis of foreign bodies.
Therefore, the increased CR3 levels on sarcoid AM may
be important in the pathogenesis of this granulomatous
disorder, because CR3 fosters sensitivity to minor stimula-
tion, such as surface adherence or endotoxin.
The present study demonstrates that OAF is a change-
able complement regulatory protein.F? The enhanced OAF
expression on AM may be related to an autoprotective
mechanism allowing AM to survive and to function at sites
of complement activation in the inflammatory milieu.
Next, we examined the correlation among comple-
ment control proteins. The expression of CR1 and CR3
expression on BALF lymphocytes was correlated. Among
complement regulatory proteins, there was also a corre-
lation between MCP and OAF both on BALF lymphocytes
and on AM. Because the functional profile of MCP is
complementary to that of OAF,23 they have synergistic
activity profiles as protective proteins against comple-
ment-mediated cell damage.
The results of our correlation study indicate that the
regulation of the expression of complement control pro-
teins may display certain invariant characteristics. A study
of the substances that regulate the expression of comple-
ment control proteins may be useful for clarifying the
mechanisms underlying sarcoidosis.
Sarcoidosis is a chronic disorder characterized by the
presence of alveolitis associated with activated T lympho-
cytes and alveolar macrophages. 24,25 Thus, in the study of
the pathogenesis of this disorder, it is critical to under-
stand the mechanisms underlying the increase in the
numbers of T cells and alveolar macrophages.
In the present study we investigated the increase in the
levels of complement control proteins on BALF cells.
Although these increases may merely reflect the upregu-
lation of complement control proteins in the pulmonary
compartment, there is some possibility that differences in
the expression of complement control proteins participate
in the ongoing pathogenesis involving immune processes
in sarcoidosis.
In this paper we investigated BALF cells obtained from
smokers, ex-smokers and non-smokers. Cigarette smoke
extract can activate an alternative complement pathway,
releasing the potent complement-derived chemotactic
peptide CSa or CSa des-Arg in human serum." We have
reported that CSa increases the levels of CR1, CR3 and
OAFon neutrophils, but does not affect complement control
proteins on monocytes in human peripheral blood.'? These
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data suggest that cigarette smoke may mediate the comple-
ment control proteins on neutrophils after the increase of
Coo. However, cigarette smoke may have little effect on the
expression of complement control proteins on AM and BALF
lymphocytes, based on the data that there was no definite
difference in the levels of the complement control proteins
between smokers and non-smokers.
The size of our sample does not allow us to draw
definitive conclusions. We intend to investigate the pos-
sible involvement of complement control proteins in the
etiology of sarcoidosis and the mechanisms of regulation
of complement-related membrane proteins in the future.
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